Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Apr 24
Swedish (OMX) Biotech Industry Analysis
UpdatedApr 25, 2024
DataAggregated Company Financials
Companies68
- 7D-0.06%
- 3M-6.5%
- 1Y-5.3%
- YTD-11.6%
Last week, the Biotech industry hasn't moved much but Swedish Orphan Biovitrum is up 4.1% in that time. As for the longer term, the industry has declined 5.1% in the last year. Looking forward, earnings are forecast to grow by 38% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 25 Apr 2024 | kr178.8b | kr29.8b | -kr5,287,384,807.92 | 51.5x | -33.8x | 6x |
| Sat, 23 Mar 2024 | kr184.6b | kr29.8b | -kr5,638,389,957.11 | 58.7x | -32.7x | 6.2x |
| Mon, 19 Feb 2024 | kr177.4b | kr29.7b | -kr5,714,127,360.36 | 47.1x | -31x | 6x |
| Wed, 17 Jan 2024 | kr188.8b | kr28.7b | -kr1,199,908,981.00 | 59.7x | -157.3x | 6.6x |
| Fri, 15 Dec 2023 | kr174.7b | kr28.7b | -kr1,170,666,543.00 | 59x | -149.2x | 6.1x |
| Sun, 12 Nov 2023 | kr160.8b | kr28.7b | -kr1,265,936,686.00 | 50.6x | -127x | 5.6x |
| Tue, 10 Oct 2023 | kr156.8b | kr27.4b | -kr2,016,768,083.00 | 45.9x | -77.7x | 5.7x |
| Thu, 07 Sep 2023 | kr151.8b | kr27.4b | -kr1,966,519,055.00 | 49.8x | -77.2x | 5.6x |
| Sat, 05 Aug 2023 | kr153.8b | kr27.5b | -kr1,555,703,057.00 | 54.3x | -98.8x | 5.6x |
| Mon, 03 Jul 2023 | kr161.8b | kr26.4b | -kr1,317,402,647.00 | 45x | -122.8x | 6.1x |
| Wed, 31 May 2023 | kr165.2b | kr26.3b | -kr1,210,442,677.00 | 45.2x | -136.5x | 6.3x |
| Fri, 28 Apr 2023 | kr174.9b | kr25.5b | -kr2,144,449,920.00 | 37.1x | -81.6x | 6.9x |
| Sun, 26 Mar 2023 | kr165.5b | kr25.4b | -kr2,031,671,425.00 | 39.2x | -81.5x | 6.5x |
| Tue, 21 Feb 2023 | kr173.3b | kr25.4b | -kr2,098,281,283.00 | 37.8x | -82.6x | 6.8x |
| Thu, 19 Jan 2023 | kr179.5b | kr23.8b | -kr1,842,380,755.00 | 32.4x | -97.4x | 7.5x |
| Sat, 17 Dec 2022 | kr158.6b | kr23.8b | -kr1,838,040,816.00 | 31.2x | -86.3x | 6.7x |
| Mon, 14 Nov 2022 | kr156.0b | kr23.9b | -kr1,903,452,996.00 | 32.9x | -82x | 6.5x |
| Wed, 12 Oct 2022 | kr150.9b | kr22.9b | -kr3,333,549,724.00 | 30.5x | -45.3x | 6.6x |
| Fri, 09 Sep 2022 | kr157.2b | kr22.9b | -kr3,244,410,512.00 | 34.3x | -48.5x | 6.9x |
| Sun, 07 Aug 2022 | kr169.8b | kr22.7b | -kr3,502,700,170.00 | 35.8x | -48.5x | 7.5x |
| Tue, 05 Jul 2022 | kr155.5b | kr21.4b | -kr3,521,686,236.00 | 36.7x | -44.2x | 7.3x |
| Thu, 02 Jun 2022 | kr156.0b | kr21.4b | -kr3,524,128,445.00 | 43.3x | -44.3x | 7.3x |
| Sat, 30 Apr 2022 | kr153.5b | kr20.0b | -kr3,342,880,997.00 | 46x | -45.9x | 7.7x |
| Mon, 28 Mar 2022 | kr165.6b | kr19.7b | -kr3,081,724,978.00 | 50.5x | -53.7x | 8.4x |
| Wed, 23 Feb 2022 | kr154.6b | kr19.7b | -kr2,536,169,254.00 | 48.7x | -61x | 7.9x |
| Fri, 21 Jan 2022 | kr172.3b | kr19.1b | -kr2,041,522,338.00 | 52.2x | -84.4x | 9x |
| Sun, 19 Dec 2021 | kr188.2b | kr19.0b | -kr1,992,145,647.00 | 52.7x | -94.5x | 9.9x |
| Tue, 16 Nov 2021 | kr202.0b | kr19.0b | -kr1,429,189,004.00 | 55.5x | -141.3x | 10.6x |
| Thu, 14 Oct 2021 | kr196.8b | kr18.1b | -kr1,332,320,458.00 | 39x | -147.7x | 10.9x |
| Sat, 11 Sep 2021 | kr219.2b | kr18.1b | -kr1,339,275,285.95 | 53.8x | -163.6x | 12.1x |
| Mon, 09 Aug 2021 | kr194.8b | kr18.1b | -kr1,175,418,285.95 | 58x | -165.7x | 10.8x |
| Sun, 02 May 2021 | kr157.4b | kr17.8b | -kr1,319,393,930.10 | 43.4x | -119.3x | 8.9x |
Price to Earnings Ratio
-119.3x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 7.6x is higher than the industry's current PS ratio of 6.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 19% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | 0.92% | |
| Healthcare | 0.88% | |
| Biotech | -0.064% | |
| Biotech | -0.064% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SOBI Swedish Orphan Biovitrum | kr266.40 | 4.1% +kr3.6b | 1.7% | PE37.6x | |
| BONEX Bonesupport Holding | kr243.60 | 2.3% +kr354.9m | 165.5% | PE65.3x | |
| DMYD B Diamyd Medical | kr11.18 | 14.0% +kr215.8m | -41.0% | PS4068.4x | |
| VICO Vicore Pharma Holding | kr17.18 | 6.6% +kr118.4m | -7.3% | PB4.2x | |
| BINV BioInvent International | kr23.20 | 7.9% +kr111.9m | -18.3% | PS25x |
